Clinical Trials
Clinical Trials
DOORwaY-90 Study
*Using Common Terminology Criteria for Adverse Events v.5.0
BCLC, Barcelona Clinic Liver Cancer, ECOG, Easter Cooperative Oncology Group; EQ-5D-5L, EuroQoL 5-Dimensions 5-Level; FACT-Hep, Functional Assessment of Cancer Therapy-Hepatobiliary; HCC, hepatocellular carcinoma; LI-RADS, Liver Imaging Reporting And Data System; mRECIST, modified Response Evaluation Criteria in Solid Tumors; QoL, quality of life; SIRT, selective internal radiation therapy.
BCLC, Barcelona Clinic Liver Cancer, ECOG, Easter Cooperative Oncology Group; EQ-5D-5L, EuroQoL 5-Dimensions 5-Level; FACT-Hep, Functional Assessment of Cancer Therapy-Hepatobiliary; HCC, hepatocellular carcinoma; LI-RADS, Liver Imaging Reporting And Data System; mRECIST, modified Response Evaluation Criteria in Solid Tumors; QoL, quality of life; SIRT, selective internal radiation therapy.
Indications for Use: SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intrahepatic artery chemotherapy (IHAC) . of FUDR (Floxuridine). Consult the Instructions for Use for a complete listing of indications, contraindications, side effects, warnings, and precautions.